Replies to post #215445 on Biotech Values

[DewDiligence]

ENTA’s HCV partnership with ABBV is certainly not an impediment to an ENTA buyout by another company. Neither ABBV nor ENTA will participate in further HCV clinical development, so the ABBV-ENTA partnership is now strictly a matter of royalty payments.